Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Other injectable treatments for Lp(a) in development include Silence Therapeutics' zerlasiran, Amgen's olpasiran and pelacarsen from Novartis. Lilly is also testing muvalaplin, the only oral ...

He entered a clinical trial for a treatment similar to lepodisiran, from drugmaker Amgen. Early results showed that drug, called olpasiran, drove down Lp(a) by at least 95% within nine months.